[
 {
  "title": "Understanding Lab Tests for Longevity",
  "date": "May 18, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Lab tests can inform us about overall longevity, with a specific focus on atherosclerosis, cancer, Alzheimer’s disease, and the physical body. Lab testing fits into the overall objective of longevity. The healthcare system is set up to react to a disease rather than prevent it. The four pillars of chronic disease are atherosclerosis, cancer, neurodegenerative disease, and foundational disease. The three components of healthspan are cognitive, physical/structural, and emotional health.",
  "content_length": 489,
  "content_tokens": 98,
  "embedding": []
 },
 {
  "title": "Atherosclerosis and Lab Tests",
  "date": "May 18, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Atherosclerosis is driven first and foremost by lipid proteins. The main lipoproteins we care about are ApoB, Lp(a), and VLDL remnants. The disease requires inflammation. There are lots of inflammation markers but not all of these are specific to cardiac inflammation. Impaired endothelial function and health plays a role in the disease.",
  "content_length": 338,
  "content_tokens": 75,
  "embedding": []
 },
 {
  "title": "Cancer and Lab Tests",
  "date": "May 18, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "With cancer, we’ve made very little progress in 50 years in regards to the long-term survival rate. With metastatic cancer, it’s about a 5% improvement we’ve made in 50 years.",
  "content_length": 175,
  "content_tokens": 47,
  "embedding": []
 },
 {
  "title": "Alzheimer’s Disease and Lab Tests",
  "date": "May 18, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "With Alzheimer’s disease, we have no drugs that can reverse the dementia or even slow its progression once it sets in. Most of the efforts we put into preserving cognition are basically directly in line with the efforts we will make to reduce the risk of dementia.",
  "content_length": 264,
  "content_tokens": 53,
  "embedding": []
 },
 {
  "title": "Physical Health and Lab Tests",
  "date": "May 18, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The physical component of health is really the first thing that starts to compromise quality of life (knee pain, back pain, etc.). It occurs decades before someone dies.",
  "content_length": 169,
  "content_tokens": 34,
  "embedding": []
 },
 {
  "title": "Emotional Health and Lab Tests",
  "date": "May 18, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The emotional piece of health is by far least tethered to age. The labs are not as relevant with this piece.",
  "content_length": 108,
  "content_tokens": 24,
  "embedding": []
 },
 {
  "title": "Impaired Kidney Function",
  "date": "May 18, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "We can also measure some other indirect proxies: ADMA, SDMA. These are arginine derivatives that impair nitric oxide formation and their clearance is impaired by elevated homocysteine.",
  "content_length": 184,
  "content_tokens": 39,
  "embedding": []
 },
 {
  "title": "Metabolic Health",
  "date": "May 18, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The metabolic component is enormous. Glucose levels, insulin levels, Triglyceride levels can be measured with blood testing. Unfortunately, many doctors are assessing risk for cardiovascular disease in their patients predicated mostly on their LDL cholesterol rather than ApoB. Even looking at non HDL cholesterol is far superior than looking at LDL cholesterol.",
  "content_length": 362,
  "content_tokens": 67,
  "embedding": []
 },
 {
  "title": "Coronary Calcium Score (CAC)",
  "date": "May 18, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Age matters big time when interpreting the CAC scores. A young patient shouldn’t have any calcification. So a calcium score of zero in somebody below 50 doesn’t really help us much. In an older person, somebody who’s over 75 that has significant calcification doesn’t tell us much either. But the flip sides of those help a lot. Someone below 50 that has even a speck of calcium immediately has an increase in risk. And conversely, somebody who’s 80 who has not a speck of calcium is immediately in a lower category of risk regardless of what their biomarkers say.",
  "content_length": 564,
  "content_tokens": 130,
  "embedding": []
 },
 {
  "title": "Cancer",
  "date": "May 18, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Cancer is both a genetic and metabolic disease. After smoking, obesity is the next leading predictor of cancer. Why? It’s less about the obesity and more about the metabolic environment that accompanies obesity, i.e. hyperinsulinemia. There’s no question that this is a disease that’s heavily impacted by the underlying metabolic health of the individual, the immune function of the individual, and the ability to acquire mutations and repair them. However, the metabolic piece is pretty much the only one we can glean anything about from a standard blood test.",
  "content_length": 561,
  "content_tokens": 117,
  "embedding": []
 },
 {
  "title": "Alzheimer’s Disease",
  "date": "May 18, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "What’s driving Alzheimer’s disease? Genetics, Metabolic health, Vascular health, Inflammation, Toxins. We get pretty darn good information from the blood. We get the relevant genes. We get all the vascular stuff. We get all the metabolic stuff. We can’t get as much good info about the inflammatory stuff. And we’re pretty bad at getting the toxins because truthfully we just don’t know.",
  "content_length": 387,
  "content_tokens": 96,
  "embedding": []
 },
 {
  "title": "Healthspan and the Physical Body",
  "date": "May 18, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Important components of the physical body for healthspan: Muscle mass, Stability, Strength, Aerobic function, Anaerobic function, Freedom from pain. Where does lab testing fit into all of that? Mostly on the endocrine side. Best example would be testing for hypogonadism. People who have low testosterone, for both male or female, AND they have impaired ability to put on muscle mass.",
  "content_length": 384,
  "content_tokens": 82,
  "embedding": []
 },
 {
  "title": "Endocrine System Testing",
  "date": "May 18, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "You can also get good insight into thyroid function if you test appropriately. Meaning… looking at all the thyroid functions, not just TSH but looking at i) free T3 ii) free T4 and iii) reverse T3. Hormones there that we care about: Estradiol, Testosterone, Free testosterone (Typically 97-99% of T is bound meaning only 1-3% is free), Sex hormone binding globulin, LH, FSH, DHEA, IGF-1, Progesterone.",
  "content_length": 401,
  "content_tokens": 109,
  "embedding": []
 },
 {
  "title": "Adrenal Function and Blood Testing",
  "date": "May 18, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "You get pretty much nothing out of a blood test on adrenal. All you’re getting is total cortisol at one point in time. You really want free cortisol and to be able to sample it over a time series.",
  "content_length": 196,
  "content_tokens": 46,
  "embedding": []
 },
 {
  "title": "Fuel Partitioning System",
  "date": "May 18, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The fuel partitioning system is about what you do with the nutrients you take in, how you store them, and how you access them. We get some of that from blood testing, but much of that comes from metabolic testing such as zone 2 testing than other tests that mimic that sort of protocol.",
  "content_length": 286,
  "content_tokens": 60,
  "embedding": []
 },
 {
  "title": "Insights from Health Testing",
  "date": "May 18, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "We have really good insight into Atherosclerotic disease, Dementia risk, Sex hormones, Thyroid hormones, Metabolism. We have reasonable resolution into Fuel partitioning, Blood chemistry. We have pretty lousy resolution into Cancer, Adrenal function.",
  "content_length": 250,
  "content_tokens": 52,
  "embedding": []
 },
 {
  "title": "Understanding ApoB and Cholesterol Levels",
  "date": "May 18, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The first thing that jumps out is that he does indeed have an elevated Lp(a). An Lp(a) test is one of the five most important blood tests you should ever do, and you only need to do it one time. About 1 in 12 people in the population have elevated Lp(a). The LDL cholesterol is elevated at 149 (60th or 70th percentile). And his primary care physician likely put him on Lipitor specifically because of this finding. Although 10 milligrams is the lowest end of the typically range (10 and 80 milligrams).",
  "content_length": 503,
  "content_tokens": 118,
  "embedding": []
 },
 {
  "title": "ApoB and Atherosclerosis",
  "date": "May 18, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "ApoB is a far better proxy for risk than LDL-C. LDL-C is measuring the cholesterol concentration carried within all of the low density lipoproteins. And there’s no question that that’s correlated with outcomes, but not as strongly as either: non HDL cholesterol, because that includes the cholesterol of not just the LDL but the VLDL. But even more importantly as ApoB. And the reason is because ApoB is a marker of all atherogenic particles. Anything that causes atherosclerosis by definition has an ApoB100 on it. So that’s an LDL, a VLDL, an IDL, and an Lp(a).",
  "content_length": 563,
  "content_tokens": 146,
  "embedding": []
 },
 {
  "title": "Determining ApoB Levels",
  "date": "May 18, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Basically four things determine ApoB levels: First, it’s how well you’re able to clear the ApoB out of circulation. Next, the other three of the four things are determined by how much cargo needs to be trafficked in the lipoprotein. And those are: 1) How much cholesterol you synthesize 2) How much cholesterol (or sterol) you reabsorb 3) The amount of triglycerides (TGs) you have to carry around.",
  "content_length": 398,
  "content_tokens": 101,
  "embedding": []
 },
 {
  "title": "Lowering Cholesterol",
  "date": "May 18, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "If you want to lower the amount of lipoprotein, the first, second, third strategy is to lower the amount of cargo they have to carry. So that means lowering triglycerides and lowering cholesterol. How cholesterol gets lowered: Reducing the synthesis of cholesterol, or Reducing the reabsorption of cholesterol. NOTE: It does NOT include reducing the intake of dietary cholesterol since that features very little into how much cholesterol you have since most of that is not absorbed.",
  "content_length": 482,
  "content_tokens": 94,
  "embedding": []
 },
 {
  "title": "Cholesterol Synthesis and Measurement",
  "date": "May 18, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "There are two pathways to make cholesterol. One of those paths you have a marker, a molecule called desmosterol, which is the last molecule before you make cholesterol. And in the other pathway it’s called lathosterol. And so by measuring lathosterol and desmosterol, you get a sense of how much cholesterol a person makes.",
  "content_length": 323,
  "content_tokens": 76,
  "embedding": []
 },
 {
  "title": "Cholesterol Reabsorption and Measurement",
  "date": "May 18, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Once a patient makes cholesterol, it gets trafficked and moved all around the body. But a lot of it ends up back in the liver. It gets taken out of circulation and then gets put into bile. It then comes to a checkpoint in the gut to see if it needs to be reabsorbed. We have a transporter called the Niemann-Pick C1-Like 1 transporter that brings cholesterol into the enterocyte. There’s a checkpoint inside that enterocyte that determines if they should keep the cholesterol or excrete it.",
  "content_length": 490,
  "content_tokens": 111,
  "embedding": []
 },
 {
  "title": "Treatment Plan for Elevated Lp(a)",
  "date": "May 18, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "First thing Peter did in this patient was actually increase his atorvastatin to 20 milligrams. And more importantly, Peter added ezetimibe. “What I suspect will happen is he will have a significant reduction in ApoB as a result of that.” Target for this patient is going to be an ApoB of about 40. This is a very aggressive target because i) family history, and ii) the Lp(a) and the fact that I know that this is a very bad actor of Lp(a). NOTE: Not everybody that has elevated Lp(a) is it very high risk, but his family history tells me that this is a bad version of Lp(a).",
  "content_length": 575,
  "content_tokens": 152,
  "embedding": []
 },
 {
  "title": "Familial Hypercholesterolemia",
  "date": "May 18, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "High total cholesterol at 356 milligrams per deciliter. High LDL cholesterol at 268 milligrams per deciliter. High non HDL cholesterol is 285 milligrams per deciliter (that’s all because of their LDL — their VLDL is normal). High ApoB at 204 milligrams per deciliter. 95th to 99th percentile of LDL-C and ApoB (they are concordant in his case). Lp(a) and VLDL is completely normal. First hypothesis: He has familial hypercholesterolemia (FH) until proven otherwise. FH is a phenotypic diagnosis. There is a very, very heterogeneous set of genes that predisposes to it.",
  "content_length": 568,
  "content_tokens": 152,
  "embedding": []
 },
 {
  "title": "Cholesterol Absorption and Treatment",
  "date": "May 18, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The highest level of beta-Sitosterol and campesterol indicates that the diagnosis is probably due to a defective ATP binding cassette. The primary driver of this phenotype is that the enterocyte is not able to regulate how much cholesterol they absorb. This patient absorbs cholesterol through that Niemann-Pick C1-Like 1 transporter and they can’t get any of it out … they just accumulate all of the cholesterol they synthesize. This patient needs to be treated with a statin, but what they need more than anything is to be on ezetimibe. This patient’s functional defect is on the reabsorption of cholesterol, and that has to be the primary target of therapy. This patient will do very well on a medium dose of a statin combined with ezetimibe.",
  "content_length": 745,
  "content_tokens": 166,
  "embedding": []
 },
 {
  "title": "Lab Work for Cholesterol Diagnosis",
  "date": "May 18, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Unfortunately, it’s actually pretty rare that a non-lipidologist would do this lab work for a patient. But it is highly recommended because it helps you to see the primary issue: Triglyceride synthesis or accumulation? cholesterol synthesis? cholesterol reabsorption? LDL clearance? If you can’t have a sense of which of those things is out of whack, how can you treat this?",
  "content_length": 374,
  "content_tokens": 85,
  "embedding": []
 },
 {
  "title": "Diet and Triglyceride Management",
  "date": "May 18, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "A patient with High ApoB, low synthesis, low absorption, high triglycerides is a patient for whom your first, second, third line of defense is diet. Somebody with a triglyceride of 500 in that situation has a genetic defect on the triglyceride side and that person needs to be on a fibrate, a type of drug that lowers triglycerides.",
  "content_length": 332,
  "content_tokens": 74,
  "embedding": []
 },
 {
  "title": "Ezetimibe and LDL-C",
  "date": "May 18, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "It is not off FDA label to prescribe ezetimibe monotherapy to lower LDL-C. There have been zero ezetimibe vs placebo or vs statin monotherapy primary, or secondary, prevention trials. The Ezetimibe Lipid Lowering Trial on Prevention of Atherosclerosis in 75 or Older (EWTOPIA) trial was the first trial to look at ezetimibe alone vs diet to reduce cardiovascular events. Conclusion: compared with dietary counseling alone, the use of additional ezetimibe for primary prevention among elderly Japanese patients with LDL ≥140 mg/dl and ≥1 high-risk feature reduced CV events, primarily cardiac events, with no difference in all-cause mortality.",
  "content_length": 642,
  "content_tokens": 147,
  "embedding": []
 },
 {
  "title": "Future Case Studies",
  "date": "May 18, 2020",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "More case studies that touch on other lab results such as Oral glucose tolerance test (OGTT), Unique metabolic cases that go beyond the obvious but into the subtle stuff like: Homocysteine, Uric acid, Liver function tests, and More. There are also some really interesting endocrine cases around testosterone, male and female hormone questions, and plenty more metabolic stuff and some glucose stuff.",
  "content_length": 399,
  "content_tokens": 78,
  "embedding": []
 }
]